LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Search

Guardant Health Inc

Deschisă

SectorSănătate

108.65 4.65

Rezumat

Modificarea prețului

24h

Curent

Minim

103.58

Maxim

107

Indicatori cheie

By Trading Economics

Venit

7.2M

-93M

Vânzări

33M

265M

Marjă de profit

-34.965

Angajați

1,999

EBITDA

6.6M

-82M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

-12.38% downside

Statistici piață

By TradingEconomics

Capitalizare de piață

4.7B

14B

Deschiderea anterioară

104

Închiderea anterioară

108.65

Sentimentul știrilor

By Acuity

50%

50%

167 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Guardant Health Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 dec. 2025, 23:21 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dec. 2025, 23:14 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dec. 2025, 22:01 UTC

Principalele dinamici ale pieței

Costco Wholesale Reports Higher Monthly Sales

3 dec. 2025, 21:38 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dec. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dec. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dec. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dec. 2025, 23:10 UTC

Câștiguri

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dec. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dec. 2025, 23:06 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dec. 2025, 22:59 UTC

Achiziții, Fuziuni, Preluări

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dec. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dec. 2025, 22:20 UTC

Câștiguri

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dec. 2025, 22:19 UTC

Câștiguri

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dec. 2025, 22:17 UTC

Câștiguri

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dec. 2025, 22:16 UTC

Câștiguri

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dec. 2025, 22:15 UTC

Câștiguri

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dec. 2025, 22:10 UTC

Achiziții, Fuziuni, Preluări

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dec. 2025, 22:09 UTC

Achiziții, Fuziuni, Preluări

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dec. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 dec. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 dec. 2025, 21:49 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:23 UTC

Câștiguri

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dec. 2025, 21:19 UTC

Câștiguri

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:06 UTC

Câștiguri

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dec. 2025, 21:04 UTC

Câștiguri

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dec. 2025, 21:03 UTC

Câștiguri

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparație

Modificare preț

Guardant Health Inc Așteptări

Obiectiv de preț

By TipRanks

-12.38% jos

Prognoză pe 12 luni

Medie 92.84 USD  -12.38%

Maxim 130 USD

Minim 60 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGuardant Health Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

20

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

38.86 / 47.41Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

167 / 374 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat